JP2002525066A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002525066A5 JP2002525066A5 JP2000570351A JP2000570351A JP2002525066A5 JP 2002525066 A5 JP2002525066 A5 JP 2002525066A5 JP 2000570351 A JP2000570351 A JP 2000570351A JP 2000570351 A JP2000570351 A JP 2000570351A JP 2002525066 A5 JP2002525066 A5 JP 2002525066A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- pna
- transport
- nls
- interest
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 94
- 210000004027 cell Anatomy 0.000 claims description 87
- 238000000034 method Methods 0.000 claims description 73
- 230000032258 transport Effects 0.000 claims description 68
- 150000007523 nucleic acids Chemical class 0.000 claims description 65
- 108020004707 nucleic acids Proteins 0.000 claims description 63
- 102000039446 nucleic acids Human genes 0.000 claims description 63
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 61
- 108091034117 Oligonucleotide Proteins 0.000 claims description 56
- 239000013612 plasmid Substances 0.000 claims description 56
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 33
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 239000012528 membrane Substances 0.000 claims description 27
- 239000011230 binding agent Substances 0.000 claims description 21
- 230000027455 binding Effects 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 17
- 238000001415 gene therapy Methods 0.000 claims description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 12
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 12
- 238000012239 gene modification Methods 0.000 claims description 9
- 230000005017 genetic modification Effects 0.000 claims description 9
- 235000013617 genetically modified food Nutrition 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- 230000025308 nuclear transport Effects 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 claims description 6
- 210000002421 cell wall Anatomy 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 238000010367 cloning Methods 0.000 claims description 4
- 210000000633 nuclear envelope Anatomy 0.000 claims description 4
- 101710128836 Large T antigen Proteins 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 238000011238 DNA vaccination Methods 0.000 claims description 2
- 230000009061 membrane transport Effects 0.000 claims 3
- 102000003939 Membrane transport proteins Human genes 0.000 claims 1
- 108090000301 Membrane transport proteins Proteins 0.000 claims 1
- 238000009795 derivation Methods 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 210000004940 nucleus Anatomy 0.000 description 33
- 238000001890 transfection Methods 0.000 description 32
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 29
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 22
- 238000009396 hybridization Methods 0.000 description 22
- 230000006870 function Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 125000005647 linker group Chemical group 0.000 description 19
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 18
- 238000012546 transfer Methods 0.000 description 18
- 230000000692 anti-sense effect Effects 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 229920002873 Polyethylenimine Polymers 0.000 description 14
- 230000009466 transformation Effects 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 238000010586 diagram Methods 0.000 description 9
- 101150066555 lacZ gene Proteins 0.000 description 9
- 230000001588 bifunctional effect Effects 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 239000012096 transfection reagent Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108700008625 Reporter Genes Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000003527 eukaryotic cell Anatomy 0.000 description 6
- 230000012223 nuclear import Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000009899 alpha Karyopherins Human genes 0.000 description 5
- 108010077099 alpha Karyopherins Proteins 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000009510 drug design Methods 0.000 description 5
- 238000007876 drug discovery Methods 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 201000003883 Cystic fibrosis Diseases 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000005937 nuclear translocation Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 210000001163 endosome Anatomy 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108010061833 Integrases Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000009088 enzymatic function Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- XQPYRJIMPDBGRW-UHFFFAOYSA-N 2-[2-[2-(9h-fluoren-9-ylmethoxycarbonylamino)ethoxy]ethoxy]acetic acid Chemical compound C1=CC=C2C(COC(=O)NCCOCCOCC(=O)O)C3=CC=CC=C3C2=C1 XQPYRJIMPDBGRW-UHFFFAOYSA-N 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108091028732 Concatemer Proteins 0.000 description 1
- 238000012287 DNA Binding Assay Methods 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100035009 Holocytochrome c-type synthase Human genes 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102100036188 Importin subunit alpha-3 Human genes 0.000 description 1
- 101710118224 Importin subunit alpha-3 Proteins 0.000 description 1
- 102100036186 Importin subunit alpha-5 Human genes 0.000 description 1
- 101710118220 Importin subunit alpha-5 Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101000965899 Simian virus 40 Large T antigen Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- ACEMSBOZYKNMNV-UHFFFAOYSA-N [amino(methoxy)phosphanyl]oxymethane Chemical compound COP(N)OC ACEMSBOZYKNMNV-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 102000012012 beta Karyopherins Human genes 0.000 description 1
- 108010075890 beta Karyopherins Proteins 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 108700029760 synthetic LTSP Proteins 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9803099-2 | 1998-09-13 | ||
| SE9803099A SE9803099D0 (sv) | 1998-09-13 | 1998-09-13 | Nucleic acid transfer |
| PCT/SE1999/000398 WO2000015824A1 (en) | 1998-09-13 | 1999-03-15 | Transfer method for specific cellular localisation of nucleic acids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002525066A JP2002525066A (ja) | 2002-08-13 |
| JP2002525066A5 true JP2002525066A5 (https=) | 2006-08-17 |
Family
ID=20412578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000570351A Pending JP2002525066A (ja) | 1998-09-13 | 1999-03-15 | 核酸の特異的な細胞の局在化のための転写法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6720310B1 (https=) |
| EP (1) | EP1114172B1 (https=) |
| JP (1) | JP2002525066A (https=) |
| AT (1) | ATE435918T1 (https=) |
| AU (1) | AU3178499A (https=) |
| DE (1) | DE69941089D1 (https=) |
| DK (1) | DK1114172T3 (https=) |
| SE (1) | SE9803099D0 (https=) |
| WO (1) | WO2000015824A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9803099D0 (sv) | 1998-09-13 | 1998-09-13 | Karolinska Innovations Ab | Nucleic acid transfer |
| US6312956B1 (en) * | 1999-10-01 | 2001-11-06 | Vanderbilt University | Nuclear targeted peptide nucleic acid oligomer |
| EP1235914A2 (en) * | 1999-11-24 | 2002-09-04 | Joseph Rosenecker | Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells |
| KR100374050B1 (ko) * | 2000-07-26 | 2003-03-03 | 최수영 | 세포침투성 융합단백질, 이를 코딩하는 재조합폴리뉴클레오타이드 및 발현벡터 |
| KR100420798B1 (ko) | 2001-02-10 | 2004-03-02 | (주)알에이싸이언스 | 펩타이드 벡터 |
| SE0200531D0 (sv) * | 2002-02-22 | 2002-02-22 | Avaris Ab | Novel biomolecular complexes, method for their production and use |
| SE0201234D0 (sv) * | 2002-04-24 | 2002-04-24 | Avaris Ab | Transfer complex with added functionality and methods for its use |
| DE10393824D2 (de) * | 2002-09-23 | 2005-08-11 | Mologen Ag | Impfstoff gegen Infektionen mit Onkoviren, wie dem felinen Leukosevirus der Katze |
| WO2005052166A1 (en) * | 2003-11-29 | 2005-06-09 | Young-Jin Chae | Recombinant peptide vector comprising the gene for treatment for autoimmune diseases. |
| US20080206869A1 (en) * | 2005-01-24 | 2008-08-28 | Avaris Ab | Nucleic Acid Complex |
| US7795380B2 (en) * | 2006-06-02 | 2010-09-14 | University Of Iowa Research Foundation | Compositions and methods for nucleic acid delivery |
| EP1900820A1 (en) * | 2006-09-13 | 2008-03-19 | Amaxa AG | Nuclear transport agent and method for producing said agent |
| AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
| HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
| CA2789539A1 (en) | 2011-09-12 | 2013-03-12 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| CZ308738B6 (cs) * | 2020-01-20 | 2021-04-14 | PortalGene s.r.o. | Způsob úpravy molekuly nukleové kyseliny pro usnadění jejího přenosu do hostitelských buněk a upravená molekula nukleové kyseliny |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4274149A (en) | 1980-02-19 | 1981-06-16 | Flanagan Charles E | Binocular device for displaying elapsed time in the field of view |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US5265003A (en) | 1990-07-25 | 1993-11-23 | Power Trends | Miniaturized switching power supply with programmed level gate drive |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5641625A (en) | 1992-05-22 | 1997-06-24 | Isis Pharmaceuticals, Inc. | Cleaving double-stranded DNA with peptide nucleic acids |
| DE69233046T2 (de) | 1991-10-24 | 2004-03-04 | Isis Pharmaceuticals, Inc., Carlsfeld | Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| WO1993019768A1 (en) * | 1992-04-03 | 1993-10-14 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system |
| AU3999495A (en) | 1994-10-06 | 1996-05-02 | Buchardt, Dorte | Peptide nucleic acid conjugates |
| EP0874910A4 (en) | 1995-06-07 | 1999-04-21 | Life Technologies Inc | ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES |
| US6051429A (en) | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
| AU9570898A (en) * | 1997-09-18 | 1999-04-05 | Gene Therapy Systems, Inc. | Chemical modification of dna using peptide nucleic acid conjugates |
| SE9803099D0 (sv) | 1998-09-13 | 1998-09-13 | Karolinska Innovations Ab | Nucleic acid transfer |
| US6312956B1 (en) * | 1999-10-01 | 2001-11-06 | Vanderbilt University | Nuclear targeted peptide nucleic acid oligomer |
-
1998
- 1998-09-13 SE SE9803099A patent/SE9803099D0/xx unknown
-
1999
- 1999-03-15 WO PCT/SE1999/000398 patent/WO2000015824A1/en not_active Ceased
- 1999-03-15 AT AT99913793T patent/ATE435918T1/de not_active IP Right Cessation
- 1999-03-15 DK DK99913793T patent/DK1114172T3/da active
- 1999-03-15 US US09/787,033 patent/US6720310B1/en not_active Expired - Fee Related
- 1999-03-15 DE DE69941089T patent/DE69941089D1/de not_active Expired - Lifetime
- 1999-03-15 AU AU31784/99A patent/AU3178499A/en not_active Abandoned
- 1999-03-15 EP EP99913793A patent/EP1114172B1/en not_active Expired - Lifetime
- 1999-03-15 JP JP2000570351A patent/JP2002525066A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002525066A5 (https=) | ||
| US6720310B1 (en) | Transfer method for specific cellular localization of nucleic acids | |
| US11667903B2 (en) | Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/CAS9 | |
| Kauffman et al. | Synthetic molecular evolution of hybrid cell penetrating peptides | |
| US11767528B2 (en) | Targeted trans-splicing using CRISPR/Cas13 | |
| US20240043851A1 (en) | Non-toxic cas9 enzyme and application thereof | |
| KR102302679B1 (ko) | 가이드 rna 및 엔도뉴클레아제를 유효성분으로 포함하는 암 치료용 약학적 조성물 | |
| CN109475646A (zh) | 用于crispr/cas成分的脂质纳米颗粒制剂 | |
| Lin et al. | Tissue-specific mRNA delivery and prime editing with peptide–ionizable lipid nanoparticles | |
| WO2023102329A2 (en) | Effector proteins and uses thereof | |
| Min et al. | A composite gene delivery system consisting of polyethylenimine and an amphipathic peptide KALA | |
| Unciti-Broceta et al. | The use of solid supports to generate nucleic acid carriers | |
| Greitens et al. | The intracellular visualization of exogenous DNA in fluorescence microscopy | |
| Min et al. | Gene delivery using a derivative of the protein transduction domain peptide, K-Antp | |
| JP2002533088A (ja) | 非病原性トランスフェクションベクター | |
| CN1339068A (zh) | 转移核酸通过核被膜的细胞转运系统的用途 | |
| JP2022551931A (ja) | 改変エンドヌクレアーゼおよび関連方法 | |
| US20250302993A1 (en) | Enzyme, complex, recombinant vector, therapeutic agent for genetic disorder, and polynucleotide | |
| Maze et al. | CFTR and dystrophin encoding plasmids carrying both luciferase reporter gene, nuclear import specific sequences and triple helix sites | |
| Shalaby | Development of Non-Viral Vectors for Neuronal-Targeting of Crispr as a Therapeutic Strategy for Neurological Disorders | |
| WO2024148303A1 (en) | Rna-directed protease systems and uses thereof | |
| Economos | Peptide Nucleic Acids and CRISPR-Cas9: Mechanisms and Rational Applications for Gene Editing Systems | |
| WO2024006824A2 (en) | Effector proteins, compositions, systems and methods of use thereof | |
| WO2024107665A1 (en) | Effector proteins, compositions, systems and methods of use thereof | |
| Yu | Development of reporter mouse models to evaluate and optimize crispr/cas9 base editing therapeutics |